NOT

Ørsted issues EUR green hybrid capital securities

Retrieved on: 
Wednesday, March 13, 2024

Ørsted A/S (‘Ørsted’) announces its intention to issue a EUR benchmark size of subordinated green hybrid capital securities with first reset date after 5.75 years (NC5.75) and final maturity in 3024.

Key Points: 
  • Ørsted A/S (‘Ørsted’) announces its intention to issue a EUR benchmark size of subordinated green hybrid capital securities with first reset date after 5.75 years (NC5.75) and final maturity in 3024.
  • The purpose of the new issue is to refinance Ørsted’s EUR 500 million 2.25 % EUR hybrid capital securities issued in 2017, with first reset date on 24 November 2024, and to proactively manage Ørsted’s hybrid capital portfolio.
  • Today, Ørsted is also inviting holders of these securities to tender their holdings for purchase by Ørsted – see separate company announcement relating to the Tender Offer.
  • Ørsted’s new green hybrid capital securities are expected to receive the rating of Baa3 by Moody’s, BB by Standard and Poor’s, and BBB- by Fitch.

Tender offer for hybrid capital securities

Retrieved on: 
Wednesday, March 13, 2024

Ørsted A/S (‘Ørsted’) hereby invites holders of its:

Key Points: 
  • Ørsted A/S (‘Ørsted’) hereby invites holders of its:
    •    EUR 500,000,000 2.25 % hybrid capital securities due in 3017 (the ‘Capital Securities’; ISIN: XS1720192696)
    to tender the Capital Securities for purchase by Ørsted on the terms and subject to the conditions set out in the tender offer memorandum dated 5 March 2024 (the ‘Tender Offer Memorandum’) (the ‘Offer’).
  • The Offer is subject to the successful issuance of the subordinated green hybrid capital securities (‘New Hybrid Issue’) as also announced by Ørsted today.
  • Ørsted will pay for Capital Securities accepted by it for purchase pursuant to the Offer a Purchase Price of 98.75 %.
  • Together with Ørsted’s New Hybrid Issue, the purpose of the Offer is to refinance the Capital Securities and to proactively manage Ørsted’s hybrid capital portfolio.

Ørsted successfully issues EUR green hybrid capital securities

Retrieved on: 
Wednesday, March 13, 2024

Today, Ørsted A/S (‘Ørsted’) has priced EUR 750 million of subordinated green hybrid capital securities with final maturity on 14 March 3024 and first reset date on 14 December 2029 (NC5.75).

Key Points: 
  • Today, Ørsted A/S (‘Ørsted’) has priced EUR 750 million of subordinated green hybrid capital securities with final maturity on 14 March 3024 and first reset date on 14 December 2029 (NC5.75).
  • The purpose of the new issue is to refinance Ørsted’s EUR 500 million 2.25 % hybrid capital securities issued in 2017, which is callable at par on the first reset date, 24 November 2024, and to proactively manage Ørsted’s hybrid capital portfolio.
  • Today, Ørsted has also invited holders of these securities to tender their holdings for purchase by Ørsted – see separate company announcement relating to the Tender Offer.
  • Key details of the new EUR 750 million subordinated green hybrid capital securities:
    •    Fixed coupon until 14 December 2029: 5.125 % p.a.

Tender offer for hybrid capital securities – final results

Retrieved on: 
Wednesday, March 13, 2024

Ørsted A/S (‘Ørsted’) announces the result of its invitation to holders of its EUR 500,000,000 2.25 % green hybrid capital securities due in 3017 (ISIN: XS1720192696) (the ‘Capital Securities’), to tender any and all such Securities for purchase by Ørsted for cash (such invitation, the ‘Offer’).

Key Points: 
  • Ørsted A/S (‘Ørsted’) announces the result of its invitation to holders of its EUR 500,000,000 2.25 % green hybrid capital securities due in 3017 (ISIN: XS1720192696) (the ‘Capital Securities’), to tender any and all such Securities for purchase by Ørsted for cash (such invitation, the ‘Offer’).
  • The Offer was announced on 5 March 2024 and was made on the terms and subject to the conditions contained in the tender offer memorandum dated 5 March 2024 (the ‘Tender Offer Memorandum’).
  • Capitalised terms used in this announcement and not otherwise defined have the meaning given to them in the Tender Offer Memorandum.
  • As at the Expiration Deadline for the Offer being at 17:00 CET on 11 March 2024, EUR 249,544,000 in aggregate principal amount of the Securities was validly tendered pursuant to the Offer.

Polymetal International plc: Proposed divestment of Polymetal Group’s Russian business and notice of General Meeting

Retrieved on: 
Wednesday, March 13, 2024

Polymetal International plc (“Polymetal”, the “Company” or the “Group”) announces today that it has entered into contracts for the divestment of its Russian business for an effective total consideration of approximately US$3.69 billion (the “Transaction”).

Key Points: 
  • Polymetal International plc (“Polymetal”, the “Company” or the “Group”) announces today that it has entered into contracts for the divestment of its Russian business for an effective total consideration of approximately US$3.69 billion (the “Transaction”).
  • A quick, transparent, and sanctions-compliant exit under the terms of the proposed Transaction serves the interests of all stakeholders.
  • The completion of the divestment will allow the Group to de-risk the Company’s business, deliver stable cash flows and pursue new investment opportunities.
  • The Transaction values the Russian business at approximately US$3.69 billion [1] including third-party debt and intra-group arrangements detailed in the Circular.

Eupraxia Pharmaceuticals Announces Overnight Marketed Offering of Approximately $30 Million

Retrieved on: 
Monday, March 11, 2024

VICTORIA, British Columbia, March 11, 2024 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company, today announced the launch of an overnight marketed public offering (the “Offering”) of common shares of the Company (the “Shares”) for total gross proceeds of approximately $30 million.

Key Points: 
  • NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES
    VICTORIA, British Columbia, March 11, 2024 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company, today announced the launch of an overnight marketed public offering (the “Offering”) of common shares of the Company (the “Shares”) for total gross proceeds of approximately $30 million.
  • The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed.
  • Closing of the Offering will be subject to a number of customary conditions, including the entering into of the Underwriting Agreement and approval of the Toronto Stock Exchange.
  • The Offering will be made in Canada only by means of the base shelf prospectus and prospectus supplement.

GFG Announces Amendment of LIFE Offering Document

Retrieved on: 
Friday, March 8, 2024

SASKATOON, Saskatchewan, March 08, 2024 (GLOBE NEWSWIRE) -- GFG Resources Inc. (TSXV: GFG) (OTCQB: GFGSF) (“GFG” or the “Company”) announce that, due to a typographical error, it has filed an amended and restated offering document (“Form 45-106 F19”) dated March 8, 2024 (the “Amended and Restated Offering Document“) in connection with its previously announced private placement pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 – Prospectus Exemptions, previously announced on February 22, 2024 (see news release “GFG Announces Private Placement Financing of up to C$3.3 Million”)

Key Points: 
  • NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRES
    SASKATOON, Saskatchewan, March 08, 2024 (GLOBE NEWSWIRE) -- GFG Resources Inc. (TSXV: GFG) (OTCQB: GFGSF) (“GFG” or the “Company”) announce that, due to a typographical error, it has filed an amended and restated offering document (“Form 45-106 F19”) dated March 8, 2024 (the “Amended and Restated Offering Document“) in connection with its previously announced private placement pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 – Prospectus Exemptions, previously announced on February 22, 2024 (see news release “ GFG Announces Private Placement Financing of up to C$3.3 Million ”)

KP Tissue declares a Quarterly Dividend of $0.18 per Common Share

Retrieved on: 
Thursday, March 7, 2024

MISSISSAUGA, Ontario, March 07, 2024 (GLOBE NEWSWIRE) -- KP Tissue Inc. (“KPT”) (TSX: KPT) announced today that the Board of Directors has declared a quarterly dividend of $0.18 per common share, payable on April 15, 2024, to shareholders of record at the close of business on April 1, 2024, subject to applicable law.

Key Points: 
  • The dividends paid are designated as "eligible" dividends for the purposes of the Income Tax Act (Canada) and any similar provincial and territorial legislation.
  • The dividend is being declared in connection with the declaration of a corresponding quarterly distribution by Kruger Products in which KP Tissue holds a limited partnership interest.
  • The Corporation has a Dividend Reinvestment Plan under which eligible shareholders may elect to have their cash dividends reinvested in additional common shares of KPT.
  • Under the Plan, the Corporation will automatically reinvest for participating shareholders the cash dividends of KPT in newly issued Common Shares at a price per Common Share equal to 100% of the 5-day weighted average trading price of the Common Shares prior to the dividend payment date.

Successful completion of the initial offering on the iconic artwork from Francis Bacon 'Three Studies for Portrait of George Dyer, 1963’

Retrieved on: 
Thursday, March 7, 2024

The final offering memorandum detailing the terms of the Offering, together with the pricing statement, was published by the Company on 7 March 2024 and is available to view on its website at www.artshare002.com (the “Offering Memorandum”).

Key Points: 
  • The final offering memorandum detailing the terms of the Offering, together with the pricing statement, was published by the Company on 7 March 2024 and is available to view on its website at www.artshare002.com (the “Offering Memorandum”).
  • On Admission, the Company will have a market capitalisation of approximately EUR 50.7 million, equivalent to USD 55 million and have 550,000 Class B Shares in issue.
  • Zeus Capital Limited, a UK Investment Bank regulated by the Financial Conduct Authority in the UK, acted as sole bookrunner for the Offering.
  • Linklaters, LLP acted as legal advisers to the sole bookrunner.

Extension of the Offer Period

Retrieved on: 
Tuesday, March 5, 2024

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

Key Points: 
  • NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.
  • Art Share 002 S.A. (“Art Share 002” or the “Company”) wishes to announce a one-day extension to 6 March 2024, of its previously announced offer period (5 March 2024) in relation to the private placement of up to 550,000 class B shares of Art Share 002 (the “Class B Shares” or the “Offered Shares”) (the “Offering”) and the confirmation of the aggregate EUR price equivalent for the Offered Shares.
  • As a result, delivery of the Offered Shares against payment of the offer price is expected to take place on 8 March 2024 and the admission and trading is maintained as of 8 March 2024.
  • For questions, orders and requests for assistance in connection with the operation we direct you to:
    For more information on the Offering, please consult the preliminary offering memorandum relating to the Offering here, (the “Offering Memorandum”).